Full year 2023 product sales
The following table provides the top 20 product net sales from continuing operations in 2023, as well as the change compared with 2022:
| Brands | Net Sales (USD m) | % change (USD) | % change (cc1) | Brand classification by therapeutic area or established brands |
|---|---|---|---|---|
| Entresto | 6,035 | 30 | 31 | Cardiovascular, renal and metabolic |
| Cosentyx | 4,980 | 4 | 5 | Immunology |
| Promacta/Revolade | 2,269 | 9 | 10 | Oncology |
| Kesimpta | 2,171 | 99 | 99 | Neuroscience |
| Kisqali | 2,080 | 69 | 75 | Oncology |
| Tafinlar + Mekinist | 1,922 | 9 | 11 | Oncology |
| Tasigna | 1,848 | -4 | -3 | Oncology |
| Jakavi | 1,720 | 10 | 12 | Oncology |
| Lucentis2 | 1,475 | -21 | -20 | Established brands |
| Xolair3 | 1,463 | 7 | 9 | Immunology |
| Ilaris | 1,355 | 20 | 22 | Immunology |
| Sandostatin | 1,314 | 6 | 8 | Established brands |
| Zolgensma | 1,214 | -11 | -9 | Neuroscience |
| Pluvicto | 980 | 262 | 261 | Oncology |
| Gilenya2 | 925 | -54 | -54 | Established brands |
| Exforge Group | 713 | -4 | -1 | Established brands |
| Galvus Group | 692 | -19 | -11 | Established brands |
| Diovan Group | 613 | -6 | -1 | Established brands |
| Lutathera | 605 | 28 | 28 | Oncology |
| Gleevec/Glivec | 561 | -25 | -22 | Established brands |